{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-22-000034","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.367765+00:00","generated_at":"2026-06-22T03:40:58.797987+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Recursion reports Q3 net loss of $60.4M, initiates two clinical trials; raises $150M private placement","bullets":["Cash and cash equivalents $454.6M as of Sept 30, 2022; excludes $150.3M private placement closed Oct 27.","Revenue $13.2M (up from $2.5M YoY) on Roche-Genentech collaboration; net loss $60.4M vs $47.4M YoY.","Initiated Phase 2 TUPELO trial for REC-4881 in FAP and Phase 1 trial for REC-3964 in C. diff colitis.","Nominated REC-4881 for AXIN1/APC mutant cancers; planning Phase 2 trial; deprioritized GM2 gangliosidosis.","R&D expenses $40.8M, G&A $19.5M; both increased due to clinical progress and company growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-22-000034","json":"https://secwatch.observer/filing/0001601830-22-000034.json","markdown":"https://secwatch.observer/filing/0001601830-22-000034.md","text":"https://secwatch.observer/filing/0001601830-22-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/0001601830-22-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/rxrx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:40:58.797987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a7ec05090562fdc4a4a6b5aeabed022b0a0eb39","claim":"RECURSION PHARMACEUTICALS, INC. reported third quarter September 30, 2022 results: revenue 13.2 million.","evidence_excerpt":"Total revenue, consisting primarily of revenue from collaborative agreements, was $13.2 million for the third quarter of 2022, compared to $2.5 million for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/0001601830-22-000034-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter September 30, 2022"},{"label":"Revenue","value":"13.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}